Colistin Plus Carbapenem versus Colistin Monotherapy in the Treatment of Carbapenem-Resistant Acinetobacter baumannii Pneumonia

References

• Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Inf Dis. 2006;42(5):692–699. doi:10.1086/500202
   PubMed Web of Science ®Google Scholar
• Morfin-Otero R, Dowzicky MJ. Changes in MIC within a global collection of Acinetobacter baumannii collected as part of the tigecycline evaluation and surveillance trial, 2004 to 2009. Clin Ther. 2012;34(1):101–112. doi:10.1016/j.clinthera.2011.11.02822177546
   PubMed Web of Science ®Google Scholar
• Kim YA, Park YS, Youk T, Lee H, Lee K. Abrupt increase in rate of imipenem resistance in Acinetobacter baumannii complex strains isolated from General Hospitals in Korea and correlation with carbapenem administration during 2002–2013. Ann Lab Med. 2018;38(2):179–181. doi:10.3343/alm.2018.38.2.17929214766
   PubMed Web of Science ®Google Scholar
• Montero MM, Domene Ochoa S, Lopez Causape C, et al. Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant (XDR) Pseudomonas aeruginosa, including high-risk clones. J Global Antimicrob Resist. 2019. doi:10.1016/j.jgar.2019.04.012
   Web of Science ®Google Scholar
• Paul M, Bishara J, Levcovich A, et al. Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother. 2010;65(5):1019–1027. doi:10.1093/jac/dkq06920299494
   PubMed Web of Science ®Google Scholar
• Nasir N, Mahmood SF. Mortality in patients with respiratory and nonrespiratory carbapenem resistant-multidrug resistant acinetobacter infections. J Ayub Med Coll Abbottabad. 2017;29(3):511–513.29076697
   PubMedGoogle Scholar
• Archer A, Campbell A, D’Amato C, McLeod M, Rugg D. Putting the ICD-10-CM/PCS GEMs into practice (updated). J AHIMA. 2016;87(1):48–53.
   Google Scholar
• Clinical and Laboratory Standards Institute. CLSI supplement M100.Performance standards for antimicrobial susceptibility testing.28th ed. Wayne, PA:CLSI;2018
   Google Scholar
• Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318–327. doi:10.1016/S1473-3099(17)30753-329276051
   PubMed Web of Science ®Google Scholar
• Dhand A, Bayer AS, Pogliano J, et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Inf Dis. 2011;53(2):158–163. doi:10.1093/cid/cir340
   PubMed Web of Science ®Google Scholar
• Zusman O, Altunin S, Koppel F, Dishon Benattar Y, Gedik H, Paul M. Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis. J Antimicrob Chemother. 2017;72(1):29–39. doi:10.1093/jac/dkw37727624572
   PubMed Web of Science ®Google Scholar
• Liu X, Zhao M, Chen Y, et al. Synergistic killing by meropenem and colistin combination of carbapenem-resistant Acinetobacter baumannii isolates from Chinese patients in an in vitro pharmacokinetic/pharmacodynamic model. Int J Antimicrob Agents. 2016;48(5):559–563. doi:10.1016/j.ijantimicag.2016.07.01827670371
   PubMed Web of Science ®Google Scholar
• Gutierrez-Gutierrez B, Salamanca E, de Cueto M, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017;17(7):726–734. doi:10.1016/S1473-3099(17)30228-128442293
   PubMed Web of Science ®Google Scholar
• Kengkla K, Kongpakwattana K, Saokaew S, Apisarnthanarak A, Chaiyakunapruk N. Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis. J Antimicrob Chemother. 2018;73(1):22–32. doi:10.1093/jac/dkx36829069421
   PubMed Web of Science ®Google Scholar
• Durante-Mangoni E, Utili R, Zarrilli R. Combination therapy in severe Acinetobacter baumannii infections: an update on the evidence to date. Future Microbiol. 2014;9(6):773–789. doi:10.2217/fmb.14.3425046524
   PubMed Web of Science ®Google Scholar
• Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018;18(4):391–400. doi:10.1016/S1473-3099(18)30099-929456043
   PubMed Web of Science ®Google Scholar
• Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother. 2012;56(4):2108–2113. doi:10.1128/AAC.06268-1122252816
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Maraolo AE, Viscoli C. Pitfalls of defining combination therapy for carbapenem-resistant Enterobacteriaceae in observational studies. Eur j Clin Microb Infect Dis. 2017;36(10):1707–1709. doi:10.1007/s10096-017-3010-z
   Web of Science ®Google Scholar
• Fragkou PC, Poulakou G, Blizou A, et al. The role of minocycline in the treatment of nosocomial infections caused by multidrug, extensively drug and pandrug resistant acinetobacter baumannii: a systematic review of clinical evidence. Microorganisms. 2019;7:6. doi:10.3390/microorganisms7060159
   Web of Science ®Google Scholar
• Park HJ, Cho JH, Kim HJ, Han SH, Jeong SH, Byun MK. Colistin monotherapy versus colistin/rifampicin combination therapy in pneumonia caused by colistin-resistant Acinetobacter baumannii: a randomised controlled trial. J Global Antimicrob Resist. 2018;17:66–71. doi:10.1016/j.jgar.2018.11.016
   Web of Science ®Google Scholar
• van Duin D, Lok JJ, Earley M, et al. Colistin versus Ceftazidime-Avibactam in the treatment of infections due to carbapenem-resistant enterobacteriaceae. Clin Inf Dis. 2018;66(2):163–171. doi:10.1093/cid/cix783
   PubMed Web of Science ®Google Scholar
• Goodlet KJ, Nicolau DP, Nailor MD. In vitro comparison of ceftolozane-tazobactam to traditional beta-lactams and ceftolozane-tazobactam as an alternative to combination antimicrobial therapy for pseudomonas aeruginosa. Antimicrob Agents Chemother. 2017;61:12. doi:10.1128/AAC.01350-17
   Web of Science ®Google Scholar
• Vardakas KZ, Mavroudis AD, Georgiou M, Falagas ME. Intravenous colistin combination antimicrobial treatment vs. monotherapy: a systematic review and meta-analysis. Int j Antimicrob Agents. 2018;51(4):535–547. doi:10.1016/j.ijantimicag.2017.12.02029288723
   PubMed Web of Science ®Google Scholar